Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key ...

Medically reviewed by Smita Patel, DO Duchenne muscular dystrophy (DMD) is a rare neurological condition that causes severe muscle weakness and intellectual disability. DMD is an inherited (passed ...

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.

Muscular dystrophy is a disease caused by a genetic mutation. The muscles of muscular dystrophy patients weaken.. | Genetics ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Ezutromid was designed to treat DMD by boosting utrophin levels to compensate for the faulty dystrophin protein that is the root cause of the very rare muscle-wasting disease. Summit reported ...

Week in brief provides you an up to date collection of the latest developments in the world of genomics and omics.